GRAIL, Inc. (GRAL)
| Market Cap | 3.94B |
| Revenue (ttm) | 141.83M |
| Net Income (ttm) | -406.24M |
| Shares Out | 38.98M |
| EPS (ttm) | -11.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 503,599 |
| Open | 105.00 |
| Previous Close | 104.71 |
| Day's Range | 99.39 - 105.00 |
| 52-Week Range | 16.10 - 115.76 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 105.00 (+3.98%) |
| Earnings Date | Nov 12, 2025 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it... [Read more]
Financial Performance
In 2024, GRAIL's revenue was $125.60 million, an increase of 34.90% compared to the previous year's $93.11 million. Losses were -$2.03 billion, 38.3% more than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GRAL stock is "Strong Buy." The 12-month stock price target is $105.0, which is an increase of 3.98% from the latest price.
News
Here's Why Grail Soared, Again, in November
Early cancer detection is highly beneficial to sufferers, and Grail's Galleri test offers a solution. The company is the leader in the race for FDA approval, but it could benefit from being part of a ...
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equ...
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference
MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
Why Grail Stock Zoomed Nearly 7% Higher on Monday
The cancer diagnostics specialist received two price target increases from separate analysts. One more than doubled his on the company.
Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold
Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detec...
GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript
GRAIL, Inc. ( GRAL) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - Chief Scientific Officer & Presiden...
GRAIL Reports Third Quarter 2025 Financial Results
Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position o...
Here's Why Grail Stock Exploded Higher by 55% in October
Investors and a powerhouse Asian conglomerate are supporting Grail's development. The company's Galleri test offers the potential to screen for more than 50 different cancers in a single test.
GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
MENLO PARK, Calif. , Nov. 4, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...
Top Biotech Stocks Riding The Rally
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric...
GRAIL to Announce Third Quarter 2025 Financial Results
Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13 th MENLO PARK, Calif.
GRAIL: Buy Τhe Test That Could Redefine Cancer Screening
GRAIL moves from scientific vision to proven clinical reality, as PATHFINDER 2 confirms that multi-cancer early detection works effectively at scale. Physician and patient adoption is accelerating, su...
Grail Stock Is Up 80% Over the Past Month. Here's Why.
Grail is partnering with Samsung to move into Asia. The innovative cancer test maker just got major new sources of funding.
Odds of these speculative stocks making you money seems very slim, says Jim Cramer
CNBC's Jim Cramer discusses the day's market action and his take on speculative stocks.
Grail's CEO Sells 7,200 Shares for nearly $500,000
Robert P. Ragusa, Chief Executive Officer of GRAIL (GRAL -2.36%), reported the open-market sale of 7,239 shares for a transaction value of approximately $498,600 on Oct. 15, according to an SEC Form 4...
GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript
GRAIL, Inc. (NASDAQ:GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection October 20, 2025 8:00 AM EDT Company Participants Robert Ragusa - CEO & Director Jo...
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
MENLO PARK, Calif. , Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered in...
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up Updated Positive Predictive Value of Galleri in This Symptomatic Populati...
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer...
What's Happening With GRAIL Stock?
GRAIL shares soared 14% on October 16, 2025, after the announcement of a strategic partnership with Samsung C&T and Samsung Electronics to introduce the company's Galleri multi-cancer early detection ...
Why Grail Stock Soared 14% Higher on Thursday
Highly specialized healthcare diagnostics company Grail (GRAL 14.46%) passed muster on the stock exchange on the second-to-last trading day of the week. That was on the back of news that the company h...
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia
Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Pos...
Grail: A Speculative Buy
Grail, Inc. represents a speculative long-term investment opportunity, conditional on the FDA's approval of its Galleri multi-cancer early detection blood test and its widespread adoption among the ge...
This Cancer Detection Pioneer Is Worth a Look
Despite decades of progress in fighting it, cancer remains deadly. It is the second-leading cause of death in the United States, behind only heart disease.